secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001564590-22-028601
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics Q2 net loss $14.5M; cash $120.7M; CMO appointed; Phase 3 enrollment ongoing
--------------------------------------------------------------------------------

- Net loss $14.5M for Q2 2022 vs $11.0M in Q2 2021; R&D expenses $10.8M.
- Cash and equivalents $120.7M as of June 30, 2022; cash runway to mid-2024.
- Closed private placement of ~$96.3M net proceeds in April 2022.
- Appointed Richard Nieman, MD as Chief Medical Officer.
- ENLIGHTEN Phase 3 program enrolling; ENLIGHTEN II first patient expected Q3; enrollment complete mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000156459022028601/0001564590-22-028601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000156459022028601/lyra-8k_20220809.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer